Heterozygous signal transducer and activator of transcription 3 mutations in hyper-IgE syndrome result in altered B-cell maturation

2012 ◽  
Vol 129 (2) ◽  
pp. 559-562.e2 ◽  
Author(s):  
Almut Meyer-Bahlburg ◽  
Ellen D. Renner ◽  
Stacey Rylaarsdam ◽  
Janine Reichenbach ◽  
Lena F. Schimke ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Maturation ◽  
Signal Transducer ◽  
Hyper Ige Syndrome ◽  
B Cell Maturation ◽  
Transcription 3

scholarly journals Targeted selection of HIV-specific antibody mutations by engineering B cell maturation

Science ◽  
2019 ◽  
Vol 366 (6470) ◽  
pp. eaay7199 ◽  
Author(s):  
Kevin O. Saunders ◽  
Kevin Wiehe ◽  
Ming Tian ◽  
Priyamvada Acharya ◽  
Todd Bradley ◽  
...  
Keyword(s):  
B Cell ◽  
Specific Antibody ◽  
Cell Maturation ◽  
B Cell Maturation ◽  
Selection Of

scholarly journals B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies

2021 ◽  
Vol 12 ◽  
pp. 204062072198958
Author(s):  
Larysa Sanchez ◽  
Alexandra Dardac ◽  
Deepu Madduri ◽  
Shambavi Richard ◽  
Joshua Richter
Keyword(s):  
Multiple Myeloma ◽  
T Cell ◽  
B Cell ◽  
Targeted Therapies ◽  
Safety Data ◽  
Cell Maturation ◽  
Treatment Modalities ◽  
Cell Therapies ◽  
B Cell Maturation ◽  
B Cell Maturation Antigen

Outcomes of patients with multiple myeloma (MM) who become refractory to standard therapies are particularly poor and novel agents are greatly needed to improve outcomes in such patients. B-cell maturation antigen (BCMA) has become an important therapeutic target in MM with three modalities of treatment in development including antibody–drug conjugates (ADCs), bispecific T-cell engagers (BITEs), and chimeric antigen receptor (CAR) T-cell therapies. Early clinical trials of anti-BCMA immunotherapeutics have demonstrated extremely promising results in heavily pretreated patients with relapsed/refractory MM (RRMM). Recently, belantamab mafodotin was the first anti-BCMA therapy to obtain approval in relapsed/refractory MM. This review summarizes the most updated efficacy and safety data from clinical studies of BCMA-targeted therapies with a focus on ADCs and BITEs. Additionally, important differences among the BCMA-targeted treatment modalities and their clinical implications are discussed.

scholarly journals The CH1 and transmembrane domains of μ in the context of a γ2b transgene do not suffice to promote B cell maturation

1999 ◽  
Vol 11 (10) ◽  
pp. 1663-1671 ◽  
Author(s):  
Xuejun Shen ◽  
Grazyna Bozek ◽  
Carl A. Pinkert ◽  
Ursula Storb
Keyword(s):  
B Cell ◽  
Transmembrane Domains ◽  
Cell Maturation ◽  
B Cell Maturation

B-lymphocyte-induced maturation protein1 up-regulates the expression of B-cell maturation antigen in mouse plasma cells

2010 ◽  
Vol 37 (8) ◽  
pp. 3747-3755 ◽  
Author(s):  
Shaoli Deng ◽  
Tao Yuan ◽  
Xiaoxing Cheng ◽  
Rui Jian ◽  
Jing Jiang
Keyword(s):  
B Cell ◽  
B Lymphocyte ◽  
Plasma Cells ◽  
Cell Maturation ◽  
Mouse Plasma ◽  
B Cell Maturation ◽  
B Cell Maturation Antigen
Sign in / Sign up

Export Citation Format

Share Document